Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106
USA

Back

Chemotherapy and Target Therapy in the Management of Adult High- Grade Gliomas

Author(s): Gian Paolo Spinelli, Evelina Miele, Giuseppe Lo Russo, Massimo Miscusi, Giovanni Codacci-Pisanelli, Vincenzo Petrozza, Anselmo Papa, Luigi Frati, Carlo Della Rocca, Alberto Gulino, Silverio Tomao.

Abstract:

Adult high grade gliomas (HGG) are the most frequent and fatal primary central nervous system (CNS) tumors. Despite recent advances in the knowledge of the pathology and the molecular features of this neoplasm, its prognosis remains poor. In the last years temozolomide (TMZ) has dramatically changed the life expectancy of these patients: the association of this drug with radiotherapy (RT), followed by TMZ alone, is the current standard of care. However, malignant gliomas often remain resistant to chemotherapy (CHT). Therefore, preclinical and clinical research efforts have been directed on identifying and understanding the different mechanisms of chemo-resistance operating in this subset of tumors,in order to develop effective strategies to overcome resistance. Moreover, the evidence of alterations in signal transduction pathways underlying tumor progression, has increased the number of trials investigating molecular target agents, such as anti-epidermal growth factor receptor (EGFR) and anti- vascular endothelial growth factor (VEGF) signaling.

The purpose of this review is to point out the current standard of treatment and to explore new available target therapies in HGG.

Keywords: Anti-angiogenic agents, anti-EGFR agents, chemotherapy, high grade gliomas, target therapy, temozolomide

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 12
ISSUE: 8
Year: 2012
Page: [1016 - 1031]
Pages: 16
DOI: 10.2174/156800912803251207
Price: $58